|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.51 EUR | +1.02% |
|
+0.49% | -9.94% |
| 06-25 | Germany's Merck boosts life sciences business with $11 billion bet on Bio-Techne | RE |
| 06-25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
| Market Cap | 88.53B 101B 81.57B 76.26B 143B 9,510B 146B 979B 379B 4,688B 378B 370B 16,291B | P/E 2026 * |
11x | P/E 2027 * | 10.2x |
|---|---|---|---|---|---|
| Enterprise Value | 99B 113B 91.21B 85.28B 160B 10,634B 163B 1,094B 424B 5,242B 423B 414B 18,217B | EV / Sales 2026 * |
2.1x | EV / Sales 2027 * | 1.9x |
| Free-Float |
89% | Yield 2026 * |
5.77% | Yield 2027 * | 6.11% |
Last Transcript: Sanofi
| 1 day | +1.00% | ||
| 1 week | +0.49% | ||
| Current month | -1.05% | ||
| 1 month | -2.38% | ||
| 3 months | -8.19% | ||
| 6 months | -9.41% | ||
| Current year | -9.94% |
| 1 week | 71.25 |  | 74.94 |
| 1 month | 71.25 | | 78.43 |
| Current year | 71.25 | | 84.97 |
| 1 year | 71.25 | | 91.15 |
| 3 years | 71.25 | | 110.88 |
| 5 years | 71.25 | | 110.88 |
| 10 years | 62.88 | | 110.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 11/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 64 | 28/04/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-06 | Buy | Chief Financial Officer | 70 | 0.0000% | ||
| 06-06 | Buy | 169 | 0.0000% | |||
| 05-31 | Buy | Executive/Senior Manager | 27 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.02% | +0.49% | -9.48% | -23.86% | 101B | |
| +0.93% | +2.65% | +42.33% | +145.77% | 1,006B | |
| +1.61% | +7.22% | +60.81% | +47.98% | 589B | |
| +3.51% | +12.31% | +31.15% | +78.88% | 430B | |
| -0.92% | +5.11% | +29.26% | +21.27% | 331B | |
| -0.60% | +5.46% | +37.58% | +23.59% | 288B | |
| -1.26% | +4.99% | +29.35% | +39.68% | 285B | |
| -2.56% | +5.00% | -28.62% | -42.77% | 213B | |
| +0.40% | +4.51% | +25.85% | +55.35% | 190B | |
| -1.05% | +0.06% | +16.91% | +59.86% | 154B | |
| Average | +0.11% | +5.42% | +23.51% | +40.57% | 358.65B | |
| Weighted average by Cap. | +0.57% | +5.24% | +33.78% | +67.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.07B 53.58B 43.37B 40.55B 76.05B 5,056B 77.44B 520B 202B 2,492B 201B 197B 8,662B | 49.98B 56.9B 46.05B 43.06B 80.75B 5,369B 82.24B 552B 214B 2,647B 214B 209B 9,197B |
| Net income | 8.15B 9.27B 7.5B 7.02B 13.16B 875B 13.4B 90.04B 34.88B 431B 34.82B 34.06B 1,499B | 8.95B 10.19B 8.25B 7.71B 14.47B 962B 14.73B 98.99B 38.34B 474B 38.28B 37.44B 1,648B |
| Net Debt | 10.47B 11.92B 9.64B 9.02B 16.91B 1,124B 17.22B 116B 44.82B 554B 44.75B 43.77B 1,926B | 6.3B 7.17B 5.81B 5.43B 10.18B 677B 10.37B 69.65B 26.98B 334B 26.94B 26.35B 1,159B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | €74.51 | +1.02% | 369,660 |
| 25/06/26 | €73.76 | +0.29% | 2,357,129 |
| 24/06/26 | €73.55 | +0.11% | 2,848,925 |
| 23/06/26 | €73.47 | +1.35% | 2,682,634 |
| 22/06/26 | €72.49 | -2.23% | 3,593,538 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
Select your edition
All financial news and data tailored to specific country editions
